Molecular biology of normal melanocytes and melanoma cells

Journal of Clinical Pathology

Volumn 66, Issue 8, 2013, Pages 644-648

  Bandarchi, Bizhan ^a,b   Jabbari, Cyrus Aleksandre ^c   Vedadi, Ali ^d   Navab, Roya ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c American Specialty Laboratory   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; CONNEXIN 43; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ENDOTHELIN; INTERSTITIAL COLLAGENASE; MELANOCORTIN 1 RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 191; MICRORNA 193B; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEOCHONDROITIN SULFATE; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEMURAFENIB; WNT1 PROTEIN;

ADVANCED CANCER; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL NEVUS; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; HEREDITY; HUMAN; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MELANOMA CELL; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PUVA; REVIEW; SUN EXPOSURE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM;

MELANOMA; MOLECULAR BIOLOGY; MOLECULAR ONCOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE-ENVIRONMENT INTERACTION; HUMANS; MELANOCYTES; MELANOMA; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS;

EID: 84880583599     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201471     Document Type: Review

References (95)

1. Uong A, Zon LI. Melanocytes in development and cancer. J Cell Physiol 2010;222:38-41.
2. Larsson KB, Shaw HM, Thompson JF, et al. Primary mucosal and glans penis melanomas: The Sydney Melanoma Unit experience. Aust N Z J Surg 1999;69:121-6.
3. Oliva E, Quinn TR, Amin MB, et al. Primary malignant melanoma of the urethra: A clinicopathologic analysis of 15 cases. Am J Surg Pathol 2000;24:785-96.
4. Pandey M, Mathew A, Abraham EK, et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998;24:303-7.
5. Erickson CA, Reedy MV. Neural crest development: The interplay between morphogenesis and cell differentiation. Curr Top Dev Biol 1998;40:177-209.
6. Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signalling pathway. Nature 1998;396:370-3.
7. Kanzler B, Foreman RK, Labosky PA, et al. BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. Development 2000;127:1095-104.
8. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
9. Dupin E, Glavieux C, Vaigot P, et al. Endothelin 3 induces the reversion of melanocytes to glia through a neural crest-derived glial-melanocytic progenitor. Proc Natl Acad Sci USA 2000;97:7882-7.
10. Ikeya M, Lee SM, Johnson JE, et al. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 1997;389:966-70.
11. Dunn KJ, Williams BO, Li Y, et al. Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development. Proc Natl Acad Sci USA 2000;97:10050-5.
12. Yasumoto K, Yokoyama K, Shibata K, et al. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 1994;14:8058-70.
13. Wehrle-Haller B, Weston JA. Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development 1995;121:731-42.
14. Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8.
15. Hearing VJ, Jimenez M. Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res 1989;2:75-85.
16. Naeyaert JM, Eller M, Gordon PR, et al. Pigment content of cultured human melanocytes does not correlate with tyrosinase message level. Br J Dermatol 1991;125:297-303.
17. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-55.
18. Hermanns JF, Petit L, Martalo O, et al. Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: Effect of depigmenting agents. Dermatology 2000;201:118-22.
19. Bandarchi LM Bizhan, Navab R, Seth A, et al. From melanocyte to metastatic malignant melanoma. Dermatology Research and Practice [serial on the Internet]. 2010; 2010. http://www.hindawi.com/journals/drp/2010/583748.html.
20. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol 1996;132:444-50.
21. Beral V, Evans S, Shaw H, et al. Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol 1983;109:165-72.
22. Whiteman DC, Green AC. Melanoma and sun exposure: Where are we now? Int J Dermatol 1999;38:481-9.
23. Beitner H, Ringborg U, Wennersten G, et al. Further evidence for increased light sensitivity in patients with malignant melanoma. Br J Dermatol 1981;104:289-94.
24. Schneider JS, Moore DH II, Sagebiel RW. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi. Arch Dermatol 1994;130:1002-7.
25. Lee JY, Kapadia SB, Musgrave RH, et al. Neurotropic malignant melanoma occurring in a stable burn scar. J Cutan Pathol 1992;19:145-50.
26. Rockley PF, Trieff N, Wagner RF Jr, et al. Nonsunlight risk factors for malignant melanoma. Part I: Chemical agents, physical conditions, and occupation. Int J Dermatol 1994;33:398-406.
27. Gan BS, Colcleugh RG, Scilley CG, et al. Melanoma arising in a chronic (Marjolin's) ulcer. J Am Acad Dermatol 1995;32:1058-9.
28. Merkle T, Landthaler M, Eckert F, et al. Acral verrucous malignant melanoma in an immunosuppressed patient after kidney transplantation. J Am Acad Dermatol 1991;24:505-6.
29. Aitken J, Welch J, Duffy D, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
30. Bataille V. Genetics of familial and sporadic melanoma. Clin Exp Dermatol 2000;25:464-70.
31. Nagore E, Climent J, Planelles MD, et al. Analysis of the CDKN2A and CDK4 genes and HLA-DR and HLA-DQ alleles in two Spanish familial melanoma kindreds. Acta Dermatol Venereol 2000;80:440-2.
32. Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: An international population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1520-5.
33. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
34. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
35. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer 2003;39:1341-7.
36. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86.
37. Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003;49:865-72.
38. Flores JF, Walker GJ, Glendening JM, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996;56:5023-32.
39. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113-22.
40. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
41. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
42. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126:154-60.
43. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
44. Dhawan P, Singh AB, Ellis DL, et al. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62:7335-42.
45. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
46. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
47. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-70.
48. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988;80:1159-64.
49. Greulich KM, Utikal J, Peter RU, et al. c-MYC and nodular malignant melanoma. A case report. Cancer 2000;89:97-103.
50. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-56.
51. Morey AL, Murali R, McCarthy SW, et al. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology 2009;41:383-7.
52. Piepkorn M. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation. J Am Acad Dermatol 2000;42(5 Pt 1):741-5.
53. Karim RZ, Li W, Sanki A, et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol 2009;17:361-7.
54. Villares GJ, Dobroff AS, Wang H, et al. Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res 2009;69:6730-7.
55. Blackburn JS, Liu I, Coon CI, et al. A matrix metalloproteinase-1/ protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009;28:4237-48.
56. Campoli MR, Chang CC, Kageshita T, et al. Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96.
57. Chekenya M, Rooprai HK, Davies D, et al. The NG2 chondroitin sulfate proteoglycan: Role in malignant progression of human brain tumours. Int J Dev Neurosci 1999;17:421-35.
58. Stallcup WB. The NG2 proteoglycan: Past insights and future prospects. J Neurocytol 2002;31:423-35.
59. Kageshita T, Nakamura T, Yamada M, et al. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res 1991;51:1726-32.
60. Yang J, Price MA, Li GY, et al. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition. Cancer Res 2009;69:7538-47.
61. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004;3:6.
62. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-68.
63. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009;129: 1740-51.
64. Caramuta S, Egyhazi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010;130:2062-70.
65. Worley LA, Long MD, Onken MD, et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 2008;18:184-90.
66. Mehnert JM, McCarthy MM, Jilaveanu L, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010;41:375-84.
67. Hsu MY, Wheelock MJ, Johnson KR, et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Invest Dermatol Symp Proc 1996;1:188-94.
68. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007;1773:642-52.
69. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001;11:41-7.
70. Xu XZ, Garcia MV, Li TY, et al. Cytoskeleton alterations in melanoma: Aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol 2010;23:187-96.
71. Weed SA, Parsons JT. Cortactin: Coupling membrane dynamics to cortical actin assembly. Oncogene 2001;20:6418-34.
72. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett 2008;265:157-66.
73. Ammer AG, Weed SA. Cortactin branches out: Roles in regulating protrusive actin dynamics. Cell Motil Cytoskeleton 2008;65:687-707.
74. Oka M, Kikkawa U. Protein kinase C in melanoma. Cancer Metastasis Rev 2005;24:287-300.
75. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994;13:3329-38.
76. Xu G, Livingston DM, Krek W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA 1995;92:1357-61.
77. Frame FM, Rogoff HA, Pickering MT, et al. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene 2006;25:3258-66.
78. Rabbani F, Richon VM, Orlow I, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization. J Natl Cancer Inst 1999;91:874-81.
79. Sviatoha V, Tani E, Kleina R, et al. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. Melanoma Res 2010;20:118-25.
80. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002;198:142-56.
81. Imai MA, Oda Y, Oda M, et al. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J Cancer Res Clin Oncol 2004;130:320-6.
82. Zacharatos P, Kotsinas A, Evangelou K, et al. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 2004;203:744-53.
83. Salon C, Merdzhanova G, Brambilla C, et al. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007;26:6927-36.
84. Alla V, Engelmann D, Niemetz A, et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010;102:127-33.
85. Degenhardt Y, Huang J, Greshock J, et al. Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes Cancer 2010;49: 144-54.
86. Orgaz JL, Ladhani O, Hoek KS, et al. Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 2009;28:4147-61.
87. Sharma B, Singh S, Varney ML, et al. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 2010;14:435-42.
88. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008;267:226-44.
89. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009;22:175-86.
90. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001;33:475-9.
91. Heimerl S, Bosserhoff AK, Langmann T, et al. Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. Melanoma Res 2007;17:265-73.
92. Harris ML, Baxter LL, Loftus SK, et al. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res 2010;23:496-513.
93. Kenessey I, Simon E, Futosi K, et al. Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model. Thromb Haemost 2009;102:1265-73.
94. Koren EL, Liu PY, Lee SJ, et al. Metanalysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34.
95. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.